Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
26
pubmed:dateCreated
2001-6-25
pubmed:abstractText
We have identified 14-3-3 sigma (sigma) as a gene whose expression is lost in breast carcinomas, primarily by methylation-mediated silencing. In this report, we investigated the timing of loss of sigma gene expression during breast tumorigenesis in vivo. We analysed the methylation status of sigma in breast cancer precursor lesions using microdissection for selective tissue sampling. We found hypermethylation of sigma in 24 of 25 carcinomas (96%), 15 of 18 (83%) of ductal carcinoma in situ, and three of eight (38%) of atypical hyperplasias. None of the five hyperplasias without atypia showed sigma-hypermethylation. Unexpectedly, patients with breast cancer showed sigma hypermethylation in adjacent histologically normal breast epithelium, while this was never observed in individuals without evidence of breast cancer. Also, samples of periductal stromal breast tissue were consistently hypermethylated, underscoring the importance of selective tissue sampling for accurate assessment of 14-3-3-sigma methylation in breast epithelium. These results suggest that hypermethylation of 14-3-3-sigma occurs at an early stage in the progression to invasive breast cancer, and may occur in apparently normal epithelium adjacent to breast cancer. These results provide evidence that loss of expression of sigma is an early event in neoplastic transformation.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0950-9232
pubmed:author
pubmed:issnType
Print
pubmed:day
7
pubmed:volume
20
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3348-53
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:11423985-14-3-3 Proteins, pubmed-meshheading:11423985-Breast, pubmed-meshheading:11423985-Breast Neoplasms, pubmed-meshheading:11423985-Carcinoma, Ductal, Breast, pubmed-meshheading:11423985-Carcinoma, Intraductal, Noninfiltrating, pubmed-meshheading:11423985-Cell Transformation, Neoplastic, pubmed-meshheading:11423985-CpG Islands, pubmed-meshheading:11423985-DNA, pubmed-meshheading:11423985-DNA, Neoplasm, pubmed-meshheading:11423985-DNA Methylation, pubmed-meshheading:11423985-Disease Progression, pubmed-meshheading:11423985-Epithelial Cells, pubmed-meshheading:11423985-Exonucleases, pubmed-meshheading:11423985-Female, pubmed-meshheading:11423985-Gene Silencing, pubmed-meshheading:11423985-Humans, pubmed-meshheading:11423985-Hyperplasia, pubmed-meshheading:11423985-Leukocytes, pubmed-meshheading:11423985-Neoplasm Invasiveness, pubmed-meshheading:11423985-Neoplasm Proteins, pubmed-meshheading:11423985-Polymerase Chain Reaction, pubmed-meshheading:11423985-Precancerous Conditions, pubmed-meshheading:11423985-Proteins, pubmed-meshheading:11423985-Stromal Cells, pubmed-meshheading:11423985-Tumor Markers, Biological
pubmed:year
2001
pubmed:articleTitle
Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer.
pubmed:affiliation
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, MD 21231, USA.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't